Eli Lilly and Co (LLY)

80.26
0.52 0.65
NYSE : Health Care
Prev Close 79.74
Open 80.36
Day Low/High 80.03 / 80.65
52 Wk Low/High 67.88 / 88.48
Volume 3.61M
Avg Volume 3.44M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 88.02B
EPS 2.30
P/E Ratio 34.22
Div & Yield 2.04 (2.60%)

Latest News

Jim Cramer's 'Mad Money' Recap: Don't Touch These 'Third Rail' Stocks

Jim Cramer's 'Mad Money' Recap: Don't Touch These 'Third Rail' Stocks

The stocks we thought would be the strongest in 2016 are now losing their footing, Cramer says.

Eli Lilly (LLY) Upgraded at Goldman, Jim Cramer Weighs In

Eli Lilly (LLY) Upgraded at Goldman, Jim Cramer Weighs In

Eli Lilly (LLY) was upgraded to 'buy' from 'neutral' on Tuesday at Goldman Sachs.

Eli Lilly (LLY) Stock Higher, Upgraded at Goldman

Eli Lilly (LLY) Stock Higher, Upgraded at Goldman

Goldman Sachs upped Eli Lilly's (LLY) stock rating to 'buy' this morning, citing its solid pipeline.

Analysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More

Analysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More

Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.

Lilly Expands Use Of Salesforce Platform To Build More Apps And Put Patients At The Center Of Their Care

Lilly Expands Use Of Salesforce Platform To Build More Apps And Put Patients At The Center Of Their Care

One of the largest healthcare companies in the world embraces Salesforce to gain more insights about their patients and quickly build and release apps based on their needs

Takeover Chatter Around Clovis May Be Overdone

Takeover Chatter Around Clovis May Be Overdone

Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Eli Lilly Can't Put the Petal to the Metal

Eli Lilly Can't Put the Petal to the Metal

The stock appears to have lost its way.

An Options Play in Eli Lilly

An Options Play in Eli Lilly

I want to use a marriage of stock and ratio call spreads to create a juiced-up, covered-call approach.

Pull Those Stocks Up!

The market is just plain droopy.

Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement

Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement

Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.

Will Eli Lilly (LLY) Stock Be Helped by European Drug Recommendation?

Will Eli Lilly (LLY) Stock Be Helped by European Drug Recommendation?

Eli Lilly's (LLY) olaratumab drug for soft tissue sarcoma was recommended for approval by the European Medicines Agency on Friday.

Elanco's Antibiotic Stewardship Plan Yields Innovation, Scientific Advancements

Elanco's Antibiotic Stewardship Plan Yields Innovation, Scientific Advancements

Aggressive 8-point plan to help safeguard animal and human health makes progress, creates pipeline of alternatives to shared-class antibiotics

5 Questions and Answers Take a Measure of Biotech Investor Sentiment

5 Questions and Answers Take a Measure of Biotech Investor Sentiment

How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

I like a bearishly biased, slightly-out-of-the-money vertical put spread.

Eli Lilly (LLY) Stock Higher, Upgraded at JPMorgan

Eli Lilly (LLY) Stock Higher, Upgraded at JPMorgan

Eli Lilly's (LLY) stock rating was lifted to 'overweight' from 'neutral' at JPMorgan on Thursday morning.

Analysts' Actions -- Apple, Lululemon, Nike, Tractor Supply and More

Analysts' Actions -- Apple, Lululemon, Nike, Tractor Supply and More

Here are Thursday's top research calls, including downgrades for Apple, Lululemon Athletica, Nike and Tractor Supply.

Here's Why Investors Should Steer Clear of Opioids

Here's Why Investors Should Steer Clear of Opioids

Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

Sell These 5 Stocks Now Before They Turn Toxic

Sell These 5 Stocks Now Before They Turn Toxic

It's time to unload these toxic stocks from your portfolio.

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.

Intermediate Level Trade: Eli Lilly

Intermediate Level Trade: Eli Lilly

Consider that the $70 line of support.

Lilly And AstraZeneca Receive FDA Fast Track Designation For AZD3293, An Investigational Treatment For Early Alzheimer's Disease

Lilly And AstraZeneca Receive FDA Fast Track Designation For AZD3293, An Investigational Treatment For Early Alzheimer's Disease

AZD3293 is an oral potent small molecule BACE inhibitor in phase 3 development